Speciality Medicines came to market through an SME IPO that opened on 20 March 2026 and closed on 24 March 2026, and the shares listed on 30 March 2026 on BSE SME. The price band was ₹117 to ₹124 per share and one lot was 1000 shares, so the minimum application was ₹1,24,000. The issue size was ₹29.14 crore. The whole issue was fresh shares, so the money raised went to the company.
Skyline Financial Services Private Ltd was the registrar to the issue, and UNISTONE CAPITAL PRIVATE LIMITED was the lead manager.
As of 24 March 2026.
| Day |
|---|
| 1 |
| 2 |
| 3 |
Incorporated in the year 2021, Speciality Medicines Limited is a company involved in the marketing and distribution of finished formulations of speciality medicines across domestic and international markets. The company’s product portfolio includes a wide range of speciality pharmaceutical finished formulations products in various dosage forms, including tablets, capsules, creams, syrups, eye drops, gels, infusions, inhalers, injections, nasal sprays, ointments, ophthalmic solutions, oral solutions, sachets, and suspensions. The company operates in the following ways:
contract manufacturing of finished formulations for international markets and marketing and distribution of sourced specialty pharmaceutical products. The company has expanded to the international market with registered/pending products in countries like Jordan, Ethiopia, Uganda, Peru, and Namibia. The company’s distribution network has established strong relationships with over 20 states in India and over 35 countries worldwide. As of March 31, 2025, the company has 1 product registered overseas and 60 products in the registration process across 5 countries, generating revenue.
As of August 31, 2025, the company had a total of 18 permanent employees in various departments.
As described in the offer document.
| Metric | 31-Oct-25 | 31-Mar-25 | 31-Mar-24 |
|---|
Parth B Goyani, Goyani Sumit Babubhai. Promoter holding 59.28% before the issue and 43.44% after.
Work out the listing gain for this SME IPO
If the retail portion is not fully subscribed, every valid application is allotted in full. If it is oversubscribed, SEBI's rules require that as many applicants as possible receive at least one lot, so the shares are allotted by a computerised lottery across all valid applications, one lot each, until the retail portion is exhausted. Applying for more lots does not improve your chance in a lottery; it only increases what you receive if the issue is under-subscribed.
The basis of allotment document, published by the registrar on the allotment date, states the ratio: for example, one applicant in seven received one lot.
Allotment status is published by the registrar on its website, searchable by PAN, application number or demat account, and also on the exchange's website. Allotted shares are credited to the demat account the day before listing, and blocked money for unsuccessful applications is released the same day. The Rupix app can check allotment status by PAN once the registrar publishes it.
Shares list within three working days of the issue closing. On listing day the exchanges run a special pre-open session from nine o'clock, during which orders are collected and an opening price is discovered from them; trading in the share begins after that, usually around ten. The opening price is the listing price that appears on this page once the issue has listed, and the listing gain or loss is the difference between it and the issue price.
For a mainboard issue, the share then trades in the normal way with the exchange's price band for a new listing. For an SME issue, shares trade in lots rather than one at a time, and the market can be thin, so selling on listing day is not always possible at the opening price. Capital gains on shares sold within a year of allotment are short-term and taxed at the short-term rate.
Speciality Medicines IPO was a ₹29.14 crore book-built issue, made up entirely of a fresh issue. It was priced at ₹117–₹124 per share with a lot size of 1,000 shares; the minimum retail application was 2,000 shares (₹2,48,000). The IPO was open from March 20 to March 24, 2026 and was subscribed 2.33x. Shares listed on BSE SME on March 30, 2026 at ₹124, in line with the issue price of ₹124. Skyline Financial Services Pvt. Ltd. is the registrar.
UNISTONE CAPITAL PRIVATE LIMITED is the book running lead manager.
The price band of Speciality Medicines IPO is ₹117 to ₹124 per share.
The lot size of Speciality Medicines IPO is 1000 shares.
The minimum investment for Speciality Medicines IPO is approximately ₹2,48,000 based on the upper price band.
The allotment date of Speciality Medicines IPO is Mar 25, 2026.
You can check Speciality Medicines IPO allotment status on the registrar or stock exchange websites using your PAN or application number after allotment. You can also check the Speciality Medicines IPO allotment status on Rupix for quick and easy access.
₹117 to ₹124 per share, against a face value of ₹10. Most applicants bid at the cut-off price, the top of the band, so that the application was valid whatever price the issuer finally fixed.
One lot was 1000 shares, and every application had to be a whole number of lots. At the top of the band that made the minimum application ₹1,24,000. After listing, SME shares also trade in lots rather than one share at a time.
₹1,24,000, for one lot of 1000 shares at the top of the price band. The amount was blocked in the applicant's bank account through ASBA or a UPI mandate while the issue was open, and released on the allotment date to applicants who were not allotted shares.
It opened on 20 March 2026 and closed on 24 March 2026.
The basis of allotment was published on 25 March 2026 by Skyline Financial Services Private Ltd, and allotted shares were credited to demat accounts before listing.
The shares listed on 30 March 2026 on BSE SME.
The issue size was ₹29.14 crore. The fresh issue was 23,50,000 shares (aggregating up to ₹29.14 crore).